GlassScriptPhysician profile
James C Cripe
NPI 1679860894
$1,687.88
in general payments reported to CMS, 2019-2025
18 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $116 · 2021: $215 · 2022: $23.41 · 2023: $269 · 2024: $257 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $410.46 | 2019-2024 | Lynparza |
| Merck Sharp & Dohme LLC | $399.90 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Eisai INC. | $156.14 | 2019-2025 | |
| Sanara Medtech INC. | $129.87 | 2025 | Biasurge |
| Genmab U.S., INC. | $125.00 | 2023 | Tivdak |
| Clovis Oncology, INC. | $117.40 | 2019 | |
| Janssen Biotech, INC. | $75.37 | 2019-2025 | Erleada, Akeega, Balversa |
| Astellas Pharma US INC | $66.63 | 2024-2025 | Padcev, Veozah |
| Sumitomo Pharma America, INC. | $60.56 | 2024-2025 | Orgovyx |
| Incyte Corporation | $30.43 | 2019 | |
| Immunogen, INC. | $28.53 | 2023 | Elahere |
| Partner Therapeutics, INC. | $16.55 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.94 | 2019 | |
| Meditrina | $15.46 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $14.15 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $11.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.49 | 2019 | |
| Intuitive Surgical, INC. | $2.39 | 2023 | Da Vinci Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cripe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.